Header Logo

Connection

Joel Block to Tumor Necrosis Factor-alpha

This is a "connection" page, showing publications Joel Block has written about Tumor Necrosis Factor-alpha.
Connection Strength

0.712
  1. New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol. 2007 May; 19(3):259-64.
    View in: PubMed
    Score: 0.269
  2. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16; 359(9306):579-80.
    View in: PubMed
    Score: 0.187
  3. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther. 2008 Jan-Feb; 15(1):53-8.
    View in: PubMed
    Score: 0.070
  4. Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.
    View in: PubMed
    Score: 0.069
  5. The treatment of psoriatic arthritis. Am J Ther. 2006 Jan-Feb; 13(1):72-9.
    View in: PubMed
    Score: 0.061
  6. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004 Aug 01; 39(3):295-9.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.